On September 27, 2022, Isoray, Inc. (the “ Company” or “ Isoray”) entered into an Agreement and Plan of Merger (the “ Merger Agreement”) by and among the Company, Isoray Acquisition Corp., and wholly-owned subsidiary of the Company (“ Merger Sub”), Viewpoint Molecular Targeting, Inc. Upon the Closing, Isoray will increase the size of its Board of Directors from 4 members to not less than 5 members. Three of the directors will be designated by Isoray and 2 of the directors will be designated by Viewpoint. Lori Woods, current CEO and a director, will be one of the directors appointed by Isoray and will serve as the chairperson.

Thijs Spoor, Viewpoint's current CEO, will be one of the directors appointed by Viewpoint. The remaining directors, if any, will be mutually agreed upon by Lori Woods and Thijs Spoor.